This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Ergometrine parenteral

Updated 2 Feb 2023 | Oxytocics


Solution for injection containing ergometrine

Drugs List

  • ergometrine 500microgram/1ml injection
  • Therapeutic Indications


    Labour - management during third stage
    Post partum haemorrhage (high risk) - prevention



    Active management of the third stage of labour
    A dose of 500 micrograms administered intramuscularly following the delivery of the anterior shoulder of the infant or immediately after delivery of the baby.

    Prevention and treatment of postpartum haemorrhage
    200 micrograms to 500 micrograms of ergometrine to be given intramuscularly, following expulsion of the placenta or when bleeding occurs.

    In emergencies, ergometrine may be given intravenously at a dose of 250 micrograms to 500 micrograms.


    First and second stages of labour
    Induction of labour
    Severe cardiac disorder
    Severe hepatic impairment
    Severe hypertension
    Severe renal impairment
    Vascular disorder

    Precautions and Warnings

    Cardiac disorder
    Coronary arteriosclerosis
    Mild hepatic impairment
    Mild hypertension
    Mild renal impairment
    Multiple pregnancy
    Raynaud's syndrome

    Treatment to be prescribed under the supervision of a specialist
    If uterine bleeding persists after administration, investigate cause
    Advise patient grapefruit products may increase plasma level

    Pregnancy and Lactation


    Ergometrine is contraindicated in pregnancy. Use of ergometrine is strictly restricted to the third stage of labour.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    Ergometrine is contraindicated in breastfeeding.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Abdominal pain
    Arterial spasm
    Cardiac arrhythmias
    Chest pain
    Hypertension (transient)
    Myocardial infarction
    Pulmonary oedema


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: July 2014

    Reference Sources

    Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press [Accessed on May 6, 2014].

    Summary of Product Characteristics: Ergometrine Injection BP 0.05% w/v (hameln). Hameln pharmaceuticals Ltd. Revised July 2007.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.